CA2692412C - Treatment for anxiety - Google Patents

Treatment for anxiety Download PDF

Info

Publication number
CA2692412C
CA2692412C CA2692412A CA2692412A CA2692412C CA 2692412 C CA2692412 C CA 2692412C CA 2692412 A CA2692412 A CA 2692412A CA 2692412 A CA2692412 A CA 2692412A CA 2692412 C CA2692412 C CA 2692412C
Authority
CA
Canada
Prior art keywords
seq
anxiety
patient
peptide
arg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2692412A
Other languages
English (en)
French (fr)
Other versions
CA2692412A1 (en
Inventor
Andrew Tasker
Michael Tymianski
Kenneth Mendoza
Michael P. Belmares
David Garman
Peter S. Lu
Tracy Doucette
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NoNO Inc
Original Assignee
NoNO Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NoNO Inc filed Critical NoNO Inc
Publication of CA2692412A1 publication Critical patent/CA2692412A1/en
Application granted granted Critical
Publication of CA2692412C publication Critical patent/CA2692412C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1787—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2692412A 2007-07-03 2008-07-02 Treatment for anxiety Active CA2692412C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US94789207P 2007-07-03 2007-07-03
US60/947,892 2007-07-03
PCT/US2008/069085 WO2009006548A2 (en) 2007-07-03 2008-07-02 Treatment for anxiety

Publications (2)

Publication Number Publication Date
CA2692412A1 CA2692412A1 (en) 2009-01-08
CA2692412C true CA2692412C (en) 2017-02-07

Family

ID=40226818

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2692412A Active CA2692412C (en) 2007-07-03 2008-07-02 Treatment for anxiety

Country Status (10)

Country Link
US (2) US8008253B2 (enExample)
EP (1) EP2175873B1 (enExample)
JP (2) JP5775303B2 (enExample)
KR (1) KR101604428B1 (enExample)
CN (1) CN101827604B (enExample)
AU (1) AU2008272903B2 (enExample)
CA (1) CA2692412C (enExample)
DK (1) DK2175873T3 (enExample)
ES (1) ES2555172T3 (enExample)
WO (1) WO2009006548A2 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8008253B2 (en) 2007-07-03 2011-08-30 Andrew Tasker Treatment for anxiety
CN102088990A (zh) * 2008-05-16 2011-06-08 阿尔伯维塔公司 癫痫的治疗
JP5801197B2 (ja) 2008-09-03 2015-10-28 ノノ インコーポレイテッド 痛みの治療に関する薬剤及び方法
EP2841063A2 (en) * 2012-04-27 2015-03-04 Indiana University Research and Technology Corporation Compositions and methods for treating ptsd and related diseases
WO2015068558A1 (ja) 2013-11-05 2015-05-14 三菱樹脂株式会社 粘着剤組成物
JP6388023B2 (ja) 2014-03-10 2018-09-12 三菱ケミカル株式会社 画像表示装置構成用積層体の製造方法
UA123820C2 (uk) * 2014-05-28 2021-06-09 Ноно Інк. Хлоридна сіль пептиду tat-nr2b9c
WO2017093354A1 (en) 2015-11-30 2017-06-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Nmdar antagonists for the treatment of diseases associated with angiogenesis
TWI799903B (zh) 2016-02-08 2023-04-21 日商三菱化學股份有限公司 透明雙面黏著片及黏著片積層體
TWI818232B (zh) 2016-02-08 2023-10-11 日商三菱化學股份有限公司 透明雙面黏著片及黏著片積層體
CN107312069B (zh) * 2016-04-27 2018-11-06 拜西欧斯（北京）生物技术有限公司 兴奋性神经毒性相关损伤的治疗肽
US11229675B2 (en) 2016-04-27 2022-01-25 Biocells (Beijing) Biotech Co., Ltd. Therapeutic peptides for excitatory neurotoxicity-related injuries
CN106632601B (zh) * 2016-11-16 2020-10-20 中国科学院昆明动物研究所 一种阻断突触长时程增强（ltp）的短肽及其应用
KR102403089B1 (ko) * 2017-07-05 2022-06-02 바이오셀즈(베이징) 바이오테크 코., 엘티디. 폴리펩타이드의 약학적으로 허용 가능한 염 및 이의 용도
EP3693001A4 (en) * 2017-09-30 2021-07-07 Biocells (Beijing) Biotech Co., Ltd. PEPTIDIC COMPOSITION ALLOWING THE TREATMENT OF INJURIES RELATED TO EXCITING NEUROTOXICITY
FR3075038B1 (fr) 2017-12-15 2020-03-06 Melchior Material And Life Science France Utilisation de la fluoroethylnormemantine pour la prevention de l'apparition et le traitement de l'anxiete
US20220370546A1 (en) * 2019-11-05 2022-11-24 Kyoto University Peptide, composition, and method for treating, preventing, or ameliorating mood disorder
CN111285923B (zh) * 2020-03-05 2023-02-03 成都奥达生物科技有限公司 一种psd-95抑制剂
CN113735938B (zh) 2021-07-30 2024-11-08 英纳氏(珠海)药业有限公司 一种神经保护多肽化合物及其应用
WO2024149230A1 (zh) * 2023-01-09 2024-07-18 北京拓界生物医药科技有限公司 一种神经保护性psd-95多肽抑制剂及其应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6723838B1 (en) * 1998-04-22 2004-04-20 Johns Hopkins University Signal transducing synaptic molecules and uses thereof
US20060148711A1 (en) * 1999-05-14 2006-07-06 Arbor Vita Corporation Molecular interactions in neurons
US6942981B1 (en) * 1999-05-14 2005-09-13 Arbor Vita Corporation Method of determining interactions with PDZ-domain polypeptides
US7595297B2 (en) * 1999-06-02 2009-09-29 Michael Tymianski Method of reducing injury to mammalian cells
US6369076B1 (en) 1999-10-29 2002-04-09 Merck & Co. Inc. 5-benzyl-octahydroindole and 6-benzyl-decahydroquinoline NMDA/NR2B antagonists
US6432985B2 (en) 2000-04-25 2002-08-13 Hoffmann-La Roche Inc. Neuroprotective substituted piperidine compounds with activity as NMDA NR2B subtype selective antagonists
WO2002000629A1 (en) 2000-06-26 2002-01-03 Merck & Co., Inc. Iminopyrimidine nmda nr2b receptor antagonists
FI20012082A0 (fi) * 2001-10-26 2001-10-26 Paeivi Liesi Biologisesti aktiiviset peptidit hermovauroiden korjaamiseksi
US6713490B2 (en) * 2002-04-26 2004-03-30 Pfizer, Inc. 3,4-dihydroquinolin-2(1H)-one compounds as NR2B receptor antagonists
CA2505479A1 (en) * 2002-11-14 2004-06-03 Arbor Vita Corporation Molecular interactions in neurons
GB0303613D0 (en) * 2003-02-17 2003-03-19 Novartis Ag Use of organic compounds
US20050084880A1 (en) * 2003-07-11 2005-04-21 Ronald Duman Systems and methods for diagnosing & treating psychological and behavioral conditions
CA2544981A1 (en) * 2003-11-12 2005-05-26 Merck & Co., Inc. 4-phenyl piperidine sulfonyl glycine transporter inhibitors
HU226977B1 (en) * 2004-07-29 2010-04-28 Richter Gedeon Nyrt Kynurenic acid amide derivatives, pharmaceutical compositions containing them and process for producing them
US20060167075A1 (en) * 2005-01-25 2006-07-27 Pearson James P Modulators of FAAH
TW200640529A (en) * 2005-02-28 2006-12-01 Thomas Christian Lines Composition for treating mental health disorders
CA2613012A1 (en) * 2005-06-23 2007-01-04 Arbor Vita Corporation Methods and compositions for modulating cox
KR101384572B1 (ko) 2005-12-30 2014-04-24 아버 비타 코포레이션 Ｐｄｚ 상호작용의 소형 분자 억제제
US8262847B2 (en) * 2006-12-29 2012-09-11 Lam Research Corporation Plasma-enhanced substrate processing method and apparatus
US8008253B2 (en) 2007-07-03 2011-08-30 Andrew Tasker Treatment for anxiety
US8080518B2 (en) * 2007-12-05 2011-12-20 Arbor Vita Corporation Co-administration of an agent linked to an internalization peptide with an anti-inflammatory

Also Published As

Publication number Publication date
CN101827604A (zh) 2010-09-08
AU2008272903A8 (en) 2010-05-06
EP2175873A4 (en) 2011-10-05
JP2014129353A (ja) 2014-07-10
JP5775303B2 (ja) 2015-09-09
JP2010532761A (ja) 2010-10-14
KR101604428B1 (ko) 2016-03-17
US20090036376A1 (en) 2009-02-05
ES2555172T3 (es) 2015-12-29
AU2008272903A1 (en) 2009-01-08
DK2175873T3 (en) 2015-12-14
EP2175873B1 (en) 2015-11-11
CA2692412A1 (en) 2009-01-08
US8008253B2 (en) 2011-08-30
CN101827604B (zh) 2014-05-07
US20120083449A1 (en) 2012-04-05
WO2009006548A3 (en) 2009-03-19
WO2009006548A2 (en) 2009-01-08
KR20100038366A (ko) 2010-04-14
EP2175873A2 (en) 2010-04-21
US8536129B2 (en) 2013-09-17
AU2008272903B2 (en) 2013-08-29

Similar Documents

Publication Publication Date Title
DK2175873T3 (en) Peptide inhibitors of nmda receptors for use for the treatment of anxiety disorders
CA2724483C (en) Psd-95 inhibitor for the treatment of epilepsy
CA2657665C (en) Method and compositions for treating stroke with fever
ES2446292T3 (es) Tratamiento del accidente cerebrovascular y otras enfermedades sin inhibir los canales de calcio de tipo N
Klopstein et al. Beneficial effects of αB-crystallin in spinal cord contusion injury
CN107312069A (zh) 兴奋性神经毒性相关损伤的治疗肽
de Sousa Chambel Urinary Dysfunction After Spinal Cord Injury Resolving Neuronal Mechanisms Behind Neurogenic Detrusor Overactivity
Chambel Urinary dysfunction after spinal cord injury: resolving neuronal mechanisms behind neurogenic detrusor overactivity
Donev Ion Channels as Therapeutic Targets, Part B

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20130620

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251224

H13 Ip right lapsed

Free format text: ST27 STATUS EVENT CODE: N-4-6-H10-H13-H100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE AND LATE FEE NOT PAID BY DEADLINE OF NOTICE

Effective date: 20260323

H13 Ip right lapsed

Free format text: ST27 STATUS EVENT CODE: N-6-6-H10-H13-H100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE AND LATE FEE NOT PAID BY DEADLINE OF NOTICE

Effective date: 20260407

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260619